Efficacy and Safety of Crocin Supplementation in Patients With Central SerousChorioretinopathy (CSCR)

Phase 2

Recruiting

Conditions: Central serous chorioretinopathy.
Central serous chorioretinopathy
H35.71

Registration Number: IRCT20110811007297N7

Lead Sponsor: Shiraz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 40

Inclusion Criteria

age of 18-60 years old
The diagnosis of CSCR based on clinical and imagining evaluation
informed consent

Exclusion Criteria

Chronic Central SerousChorioretinopathy (CSCR)
Laser treatment (6 months prior to enrollment)
Intravitreal injection (3 months prior to enrollment)
Other retinal diseases
History of eye diseases
Diabetes Mellitus
Renal or hepatic diseases
Allergy to saffron or crocin
Pregnancy or lactation
Beta-blocker, diuretic, or corticosteroid (1 week prior to enrollment)
Bleeding tendency or any coagulation disorder

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Best-corrected visual acuity (BCVA). Timepoint: 8 weeks. Method of measurement: Snellen chart.;Foveal thickness. Timepoint: 8 weeks. Method of measurement: Optical coherence tomography (OCT).;Subretinal fluid height. Timepoint: 8 weeks. Method of measurement: Optical coherence tomography (OCT).;Subfoveal choroidal thickness. Timepoint: 8 weeks. Method of measurement: Optical coherence tomography (OCT).;Need to Laser Therapy. Timepoint: 8 weeks. Method of measurement: clinical evaluation.;Safety and tolerability. Timepoint: 8 weeks. Method of measurement: based on patients reported adverse events.

Secondary Outcome Measures